Table 18.8 Myeloma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races				Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females	
-Year Relative Survival	(Percent)									
Year of Diagnosis:	(I CI CCIIC)									
1960-1963 ^a	_	_	_	12	13	10	_	_	_	
1970-1973 ^a	_	_	_	19	20	17	-	-	_	
1975–1977 ^b	24.6	24.0	25.3	24.1	23.6	24.7	29.5	29.3	29.5	
1978–1980 ^b	24.0	24.0	27.5	24.1	23.0	25.5	32.5	29.3	37.5	
1981–1983 ^b	25.9	24.4	29.4	24.8	24.2	29.0	28.9	27.4	27.9	
1981-1985 1984-1986 ^b	27.8	27.6	29.4	27.2	25.4	29.0	31.8	33.3	30.3	
1987-1989 ^b	27.2	28.9	25.5	26.9	29.1	24.5	30.0	29.7	30.3	
1990-1992 ^b	29.2	30.4	27.9	28.3	29.5	26.9	34.3	38.1	30.7	
1993-1995 ^b	31.6	32.1	31.2	30.5	31.2	29.7	35.1	34.7	35.5	
1996-1998 ^b	32.3	34.4	30.2	32.2	34.2	29.9	30.9	32.4	29.8	
1999-2003 ^b	36.9	38.7	34.7	37.0	39.0	34.6	36.5	38.7	34.5	
2004-2010 ^b	46.7 ^f	47.5 ^f	45.8 ^f	46.8 ^f	48.6 ^f	44.6 ^f	46.5 ^f	43.5 ^f	49.2 ^f	
-Year Period Survival (P	ercent) ^{cd}									
2010	46.3	47.4	45.1	46.3	48.2	43.9	45.8	44.2	47.4	
	0.4 0.01.0CP									
Stage Distribution (%) 20	04-2010-2									
All Stages										
Number of cases	28,326	15,384	12,942	20,855	11,675	9,180	5,487	2,664	2,823	
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%	
Localized	5	б	4	5	6	4	4	5	4	
Regional	0	0	0	0	0	0	0	0	0	
Distant	95	94	96	95	94	96	96	95	96	
Unstaged	0	0	0	0	0	0	0	0	0	
-Year Relative Survival	(Percent) 2	004-2010 ^c								
Age at Diagnosis:	(10100110)) / 1	001 2020								
Ages <45	68.3	69.0	67.4	67.9	69.1	65.6	67.1	66.3	67.5	
Ages 45-54	61.1	60.5	62.0	63.2	63.6	62.7	54.2	49.6	59.4	
Ages 55-64	54.0	53.7	54.4	54.0	54.4	53.5	52.9	51.2	54.9	
	54.0 43.6	53.7 43.1	54.4 44.2	54.0 44.4	54.4 44.0	53.5 45.1	52.9 41.2	5⊥.∠ 39.7	54.9 42.6	
Ages 65-74										
Ages 75+	26.9	28.1	25.7	27.5	29.8	25.4	24.4	22.8	25.5	
Ages <65	57.8	57.5	58.3	58.3	58.8	57.5	55.2	52.3	58.5	
Ages 65+	34.9	36.0	33.8	35.3	37.0	33.5	33.8	33.5	34.1	
Stage ^e :										
All Stages	44.9	46.0	43.5	44.8	46.7	42.4	44.9	44.1	45.8	
Localized	66.9	70.8	60.2	68.2	73.1	58.7	55.8	54.5 ^g	57.1 ^g	
Regional		-	-		-	-	-			
Distant	43.7	44.5	42.8	43.5	45.0	41.7	44.4	43.6	45.3	
									10.0	

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Based on follow-up of patients into 2011.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2011.

Period survival provides a 2010 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2007-2009: 0-1 year survival),

(2006-2008: 1-2 year survival), (2005-2007: 2-3 year survival), (2004-2006: 3-4 year survival), (2003-2005: 4-5 years survival). Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding. The difference between 1975-1977 and 2004-2010 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

b

С

d

e

f

g

h

_

Statistic could not be calculated due to fewer than 25 cases during the time period.